GlaxoSmithKline PLC Director/PDMR Shareholding (4139F)
20 Febbraio 2018 - 2:17PM
UK Regulatory
TIDMGSK
RNS Number : 4139F
GlaxoSmithKline PLC
20 February 2018
GlaxoSmithKline plc (the 'Company')
Shares sold to meet tax liabilities
Following the vesting of awards granted in 2015 under the
GlaxoSmithKline 2009 Performance Share Plan on 15 February 2018 and
as notified on 16 February 2018, the notifications that follow
reflect changes in the interests of Persons Discharging Managerial
Responsibilities ('PDMRs') in Ordinary Shares and in American
Depositary Shares ('ADSs') of the Company arising from the sale of
Ordinary Shares or ADSs to meet tax liabilities.
Transaction notification
1. Details of PDMR/person closely associated
with them ('PCA')
=== ======================================================
a) Name Ms E Walmsley
=== ====================== ==============================
b) Position/status Chief Executive Officer
=== ====================== ==============================
c) Initial notification/ Initial notification
amendment
=== ====================== ==============================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ======================================================
a) Name GlaxoSmithKline plc
=== ====================== ==============================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ==============================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================
a) Description Ordinary shares of 25 pence
of the financial each ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ==============================
b) Nature of The sale of Ordinary Shares
the transaction to meet tax liabilities for
the vesting of awards granted
in 2015 under the Company's
2009 Performance Share Plan.
=== ====================== ==============================
c) Price(s) Price(s) Volume(s)
and volume(s) ------------ ----------
GBP13.0726 65,247
------------ ----------
=== ====================== ==============================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ==============================
e) Date of the 2018-02-16
transaction
=== ====================== ==============================
f) Place of London Stock Exchange (XLON)
the transaction
=== ====================== ==============================
1. Details of PDMR/person closely associated
with them ('PCA')
=== =======================================================
a) Name Mr R G Connor
=== ====================== ===============================
b) Position/status President, Global Manufacturing
and Supply
=== ====================== ===============================
c) Initial notification/ Initial notification
amendment
=== ====================== ===============================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== =======================================================
a) Name GlaxoSmithKline plc
=== ====================== ===============================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ===============================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================
a) Description Ordinary shares of 25 pence
of the financial each ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ===============================
b) Nature of The sale of Ordinary Shares
the transaction to meet tax liabilities for
the vesting of awards granted
in 2015 under the Company's
2009 Performance Share Plan.
=== ====================== ===============================
c) Price(s) Price(s) Volume(s)
and volume(s) ------------ ----------
GBP13.0726 33,446
------------ ----------
=== ====================== ===============================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ===============================
e) Date of the 2018-02-16
transaction
=== ====================== ===============================
f) Place of London Stock Exchange (XLON)
the transaction
=== ====================== ===============================
1. Details of PDMR/person closely associated
with them ('PCA')
=== =======================================================
a) Name Mr N Hirons
=== ====================== ===============================
b) Position/status SVP, Global Ethics & Compliance
=== ====================== ===============================
c) Initial notification/ Initial notification
amendment
=== ====================== ===============================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== =======================================================
a) Name GlaxoSmithKline plc
=== ====================== ===============================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ===============================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================
a) Description Ordinary shares of 25 pence
of the financial each ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ===============================
b) Nature of The sale of Ordinary Shares
the transaction to meet tax liabilities for
the vesting of awards granted
in 2015 under the Company's
2009 Performance Share Plan.
=== ====================== ===============================
c) Price(s) Price(s) Volume(s)
and volume(s) ------------ ----------
GBP13.0726 16,216
------------ ----------
=== ====================== ===============================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ===============================
e) Date of the 2018-02-16
transaction
=== ====================== ===============================
f) Place of London Stock Exchange (XLON)
the transaction
=== ====================== ===============================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ===========================================================
a) Name Mr B McNamara
=== ====================== ===================================
b) Position/status CEO, Consumer Healthcare
=== ====================== ===================================
c) Initial notification/ Initial notification
amendment
=== ====================== ===================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ===========================================================
a) Name GlaxoSmithKline plc
=== ====================== ===================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ===================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================
a) Description GlaxoSmithKline plc American
of the financial Depositary Shares ('ADSs')
instrument ISIN: US37733W1053
=== ====================== ===================================
b) Nature of The sale of ADSs to meet tax
the transaction liabilities further to the vesting
of awards granted in 2015 under
the Company's 2009 Performance
Share Plan.
=== ====================== ===================================
c) Price(s) Price(s) Volume(s)
and volume(s) --------- ----------
$37.4803 14,389
--------- ----------
=== ====================== ===================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ===================================
e) Date of the 2018-02-16
transaction
=== ====================== ===================================
f) Place of New York Stock Exchange (XNYS)
the transaction
=== ====================== ===================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ======================================================
a) Name Mr D S Redfern
=== ====================== ==============================
b) Position/status Chief Strategy Officer
=== ====================== ==============================
c) Initial notification/ Initial notification
amendment
=== ====================== ==============================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ======================================================
a) Name GlaxoSmithKline plc
=== ====================== ==============================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ==============================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================
a) Description Ordinary shares of 25 pence
of the financial each ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ==============================
b) Nature of The sale of Ordinary Shares
the transaction to meet tax liabilities for
the vesting of awards granted
in 2015 under the Company's
2009 Performance Share Plan.
=== ====================== ==============================
c) Price(s) Price(s) Volume(s)
and volume(s) ------------ ----------
GBP13.0726 26,605
------------ ----------
=== ====================== ==============================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ==============================
e) Date of the 2018-02-16
transaction
=== ====================== ==============================
f) Place of London Stock Exchange (XLON)
the transaction
=== ====================== ==============================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ======================================================
a) Name Ms C Thomas
=== ====================== ==============================
b) Position/status SVP, Human Resources
=== ====================== ==============================
c) Initial notification/ Initial notification
amendment
=== ====================== ==============================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ======================================================
a) Name GlaxoSmithKline plc
=== ====================== ==============================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ==============================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================
a) Description Ordinary shares of 25 pence
of the financial each ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ==============================
b) Nature of The sale of Ordinary Shares
the transaction to meet tax liabilities for
the vesting of awards granted
in 2015 under the Company's
2009 Performance Share Plan.
=== ====================== ==============================
c) Price(s) Price(s) Volume(s)
and volume(s) ------------ ----------
GBP13.0726 35,473
------------ ----------
=== ====================== ==============================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ==============================
e) Date of the 2018-02-16
transaction
=== ====================== ==============================
f) Place of London Stock Exchange (XLON)
the transaction
=== ====================== ==============================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ========================================================
a) Name Mr P C Thomson
=== ====================== ================================
b) Position/status SVP, Communications & Government
Affairs
=== ====================== ================================
c) Initial notification/ Initial notification
amendment
=== ====================== ================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ========================================================
a) Name GlaxoSmithKline plc
=== ====================== ================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================
a) Description Ordinary shares of 25 pence
of the financial each ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ================================
b) Nature of The sale of Ordinary Shares
the transaction to meet tax liabilities for
the vesting of awards granted
in 2015 under the Company's
2009 Performance Share Plan.
=== ====================== ================================
c) Price(s) Price(s) Volume(s)
and volume(s) ------------ ----------
GBP13.0726 20,524
------------ ----------
=== ====================== ================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ================================
e) Date of the 2018-02-16
transaction
=== ====================== ================================
f) Place of London Stock Exchange (XLON)
the transaction
=== ====================== ================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ===========================================================
a) Name Mr D E Troy
=== ====================== ===================================
b) Position/status SVP & General Counsel
=== ====================== ===================================
c) Initial notification/ Initial notification
amendment
=== ====================== ===================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ===========================================================
a) Name GlaxoSmithKline plc
=== ====================== ===================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ===================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ===========================================================
a) Description GlaxoSmithKline plc American
of the financial Depositary Shares ('ADSs')
instrument ISIN: US37733W1053
=== ====================== ===================================
b) Nature of The sale of ADSs to meet tax
the transaction liabilities further to the vesting
of awards granted in 2015 under
the Company's 2009 Performance
Share Plan.
=== ====================== ===================================
c) Price(s) Price(s) Volume(s)
and volume(s) --------- ----------
$37.4803 31,635
--------- ----------
=== ====================== ===================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ===================================
e) Date of the 2018-02-16
transaction
=== ====================== ===================================
f) Place of New York Stock Exchange (XNYS)
the transaction
=== ====================== ===================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ======================================================
a) Name Dr P J T Vallance
=== ====================== ==============================
b) Position/status President, R&D
=== ====================== ==============================
c) Initial notification/ Initial notification
amendment
=== ====================== ==============================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ======================================================
a) Name GlaxoSmithKline plc
=== ====================== ==============================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ==============================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================
a) Description Ordinary shares of 25 pence
of the financial each ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ==============================
b) Nature of The sale of Ordinary Shares
the transaction to meet tax liabilities for
the vesting of awards granted
in 2015 under the Company's
2009 Performance Share Plan.
=== ====================== ==============================
c) Price(s) Price(s) Volume(s)
and volume(s) ------------ ----------
GBP13.0726 73,783
------------ ----------
=== ====================== ==============================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ==============================
e) Date of the 2018-02-16
transaction
=== ====================== ==============================
f) Place of London Stock Exchange (XLON)
the transaction
=== ====================== ==============================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ======================================================
a) Name Mrs V A Whyte
=== ====================== ==============================
b) Position/status Company Secretary
=== ====================== ==============================
c) Initial notification/ Initial notification
amendment
=== ====================== ==============================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ======================================================
a) Name GlaxoSmithKline plc
=== ====================== ==============================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ==============================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================
a) Description Ordinary shares of 25 pence
of the financial each ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ==============================
b) Nature of The sale of Ordinary Shares
the transaction to meet tax liabilities for
the vesting of awards granted
in 2015 under the Company's
2009 Performance Share Plan.
=== ====================== ==============================
c) Price(s) Price(s) Volume(s)
and volume(s) ------------ ----------
GBP13.0726 4,544
------------ ----------
=== ====================== ==============================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ==============================
e) Date of the 2018-02-16
transaction
=== ====================== ==============================
f) Place of London Stock Exchange (XLON)
the transaction
=== ====================== ==============================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHXBLFLVLFFBBZ
(END) Dow Jones Newswires
February 20, 2018 08:17 ET (13:17 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024
